Financial targets

Financial targets

In line with its strategy and priorities for 2026–2028, Bioretec’s new financial targets are:

• Reach net sales exceeding EUR 10 million by the end of the year 2028
• Maintain an average sales margin exceeding 70% during the strategy period

While maintaining a healthy sales margin enables efficient scaling, Bioretec does not expect to reach cash flow positivity or profitability during the strategy period due to the planned strategic investments in R&D and commercialization. The financial targets do not include assumptions of revenue or funding from potential partnership or licensing opportunities within the strategy period.

Bioretec does not consider these financial targets as market guidance for any given year.

Dividend policy

No dividend shall be distributed.